Extended Data Fig. 10. Sensitisation to anti-PD1 negatively correlates to abundance of tumour-resident neutrophils.
Abundance of specific immune cells in a tumor, b tumour-draining lymph node and c spleen in untreated mice (n = 4–8 individual samples). d Schematic of the experimental plan and dosing regimen for Hcmel12 tumors with anti-PD1 monoclonal antibody (mAb) and either G-CSF or anti-Ly6G. e Tumor weight of untreated mice compared to mice treated with G-CSF or anti-Ly6G (n = 8, 8, 7, 8, 7, 8, 7, 7, 7 and 7 individual tumours). Log2 fold change of tumor neutrophils in untreated and treated mice relative to untreated control for f G-CSF and g anti-Ly6G (n = 4–8 individual tumours). Tumor weight of mice treated with anti-PD1 or anti-PD1 and h G-CSF (n = 8, 7, 8, 8, 8, 7 and 7 individual tumours) or i anti-Ly6G (n = 8, 8, 8, 7, 8 and 8 individual tumours). Natural Killer T-cells: CD4- CD8- NK1.1+. Macrophages: Cd11b+ Ly6C- F4/80+. Neutrophils: CD11b+ Ly6C+ Ly6G+. All P-values were determined using a one-way ANOVA test with Fisher’s LSD Test (A-C,E-I). Error bars indicate SD. Measure of centrality is mean. * P = < 0.05, ** P = <0.01, **** P = <0.0001. Number of replicates are described across conditions from left to right as presented. Heatmap representations of data where asterisks are not present report non-significant changes.